Abstract PO1-20-04: STX-478-101: A phase 1/2, first-in-human study of STX-478 monotherapy or in combination with fulvestrant in patients with breast cancer or other advanced solid tumors (trial in progress)
Year: 2024
Type: conference-abstract
Source: Cancer Research
Authors: Alberto Montero, Douglas Orr, Pamela Munster, Patricia LoRusso, Komal Jhaveri, Timothy Pluard, Ira Winer, Michael Streit, Monica Patterson, Simon Roberts, Stefani Corsi-Travali, Courtney Ewert, Dejan Juric
Institutions: University Hospitals Seidman Cancer Center, Case Western Reserve University, Mary Crowley Cancer Research Center, University of California, San Francisco, Yale Cancer Center, Memorial Sloan Kettering Cancer Center, University of Missouri–Kansas City, The Barbara Ann Karmanos Cancer Institute, Scorpion Therapeutics (United States), Harvard University, Massachusetts General Hospital
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4396590583